Advaxis, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based antigen delivery product in the United States. It is developing therapies for HPV-related cancers using axalimogene filolisbac (AXAL) for the treatment of head and neck cancer. The company is also developing ADXS-PSA for the treatment of prostate cancer; and ADXS-NEO, an individualized Lm technology antigen delivery product candidate that is designed to create individualized therapies by activating the patient's immune system to respond against multiple mutations or neoantigens.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone609-452-9813
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$6.06 million
Profitability
Miscellaneous
Employees58
Next Earnings Date1/9/2020 (Estimated)
OptionableOptionable
Advaxis (NASDAQ:ADXS) Frequently Asked Questions
What is Advaxis' stock symbol?
Advaxis trades on the NASDAQ under the ticker symbol "ADXS."
How were Advaxis' earnings last quarter?
Advaxis, Inc. (NASDAQ:ADXS) issued its quarterly earnings results on Tuesday, March, 12th. The biotechnology company reported $0.18 EPS for the quarter, beating analysts' consensus estimates of ($0.25) by $0.43. The biotechnology company had revenue of $19.69 million for the quarter. Advaxis had a negative return on equity of 67.08% and a negative net margin of 113.67%. View Advaxis' Earnings History.
When is Advaxis' next earnings date?
What price target have analysts set for ADXS?
1 Wall Street analysts have issued 1-year price objectives for Advaxis' shares. Their forecasts range from $4.00 to $4.00. On average, they expect Advaxis' stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 1,262.9% from the stock's current price. View Analyst Price Targets for Advaxis.
What is the consensus analysts' recommendation for Advaxis?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Advaxis in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Advaxis.
What are Wall Street analysts saying about Advaxis stock?
Here are some recent quotes from research analysts about Advaxis stock:
- 1. According to Zacks Investment Research, "Advaxis, Inc. is a development stage biotechnology company focused on developing safe and effective cancer vaccines that utilize multiple mechanisms of immunity. The Company is developing a live Listeria vaccine technology under license from the University of Pennsylvania which secretes a protein sequence containing a tumor-specific antigen. The Company believes this vaccine technology is capable of stimulating the body's immune system to process and recognize the antigen as if it were foreign, generating an immune response able to attack the cancer. It also considers this to be a broadly enabling platform technology that can be applied to the treatment of many types of cancers, infectious diseases and auto-immune disorders. The Company's products in development include Lovaxin C and Lovaxin B, Lovaxin P. " (8/9/2019)
- 2. HC Wainwright analysts commented, "We maintain our Neutral rating of ADXS and our 12-month price target of $4.30 per share. We derive our price target based on the average of two valuation methods: (1) price-sales multiple (6x 2026 sales estimate at 20% discount); and (2) price-earnings multiple (19x 2026 earnings estimate at 20% discount)." (6/12/2019)
Has Advaxis been receiving favorable news coverage?
Headlines about ADXS stock have been trending somewhat negative this week, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Advaxis earned a media sentiment score of -1.3 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Advaxis.
Are investors shorting Advaxis?
Advaxis saw a decrease in short interest in the month of August. As of August 31st, there was short interest totalling 584,200 shares, a decrease of 12.0% from the July 31st total of 663,500 shares. Based on an average daily trading volume, of 538,900 shares, the short-interest ratio is presently 1.1 days. Currently, 3.5% of the shares of the stock are short sold. View Advaxis' Current Options Chain.
Who are some of Advaxis' key competitors?
Some companies that are related to Advaxis include ProPhase Labs (PRPH), Sophiris Bio (SPHS), RegeneRx Biopharmaceuticals (RGRX), Novelion Therapeutics (NVLN), Mateon Therapeutics (MATN), Tocagen (TOCA), Soligenix (SNGX), Guardion Health Sciences (GHSI), ANCHIANO THERAP/S (ANCN), Amarillo Biosciences (AMAR), Prana Biotechnology (PRAN), Tetraphase Pharmaceuticals (TTPH), Oncolytics Biotech (ONCY), Regulus Therapeutics (RGLS) and Pulmatrix (PULM).
What other stocks do shareholders of Advaxis own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Advaxis investors own include Madrigal Pharmaceuticals (MDGL), Inovio Pharmaceuticals (INO), Merck & Co., Inc. (MRK), Vistagen Therapeutics (VTGN), Celgene (CELG), Anavex Life Sciences (AVXL), Highpower International (HPJ), BIOLINERX LTD/S (BLRX), ContraVir Pharmaceuticals (CTRV) and Novavax (NVAX).
Who are Advaxis' key executives?
Advaxis' management team includes the folowing people:
- Mr. Kenneth A. Berlin J.D., Pres, CEO & Director (Age 55)
- Ms. Molly Henderson CPA, CPA, MBA, Exec. VP, CFO & Corp. Sec. (Age 48)
- Dr. Robert G. Petit, Exec. VP & Chief Scientific Officer (Age 59)
- Mr. Anthony A. Lombardo, Exec. Officer (Age 70)
- Dr. Andres A. Gutierrez, Exec. VP & Chief Medical Officer (Age 58)
Who are Advaxis' major shareholders?
Advaxis' stock is owned by many different of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (2.91%), Vanguard Group Inc. (1.34%) and JPMorgan Chase & Co. (0.30%). Company insiders that own Advaxis stock include Adage Capital Partners Gp, LL, Anthony A Lombardo, Robert Petit, Roni Appel and Sara Bonstein. View Institutional Ownership Trends for Advaxis.
Which institutional investors are buying Advaxis stock?
ADXS stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Vanguard Group Inc. and JPMorgan Chase & Co.. View Insider Buying and Selling for Advaxis.
How do I buy shares of Advaxis?
Shares of ADXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Advaxis' stock price today?
One share of ADXS stock can currently be purchased for approximately $0.2935.
How big of a company is Advaxis?
Advaxis has a market capitalization of $5.05 million and generates $6.06 million in revenue each year. The biotechnology company earns $-66,510,000.00 in net income (profit) each year or ($19.34) on an earnings per share basis. Advaxis employs 58 workers across the globe.View Additional Information About Advaxis.
What is Advaxis' official website?
How can I contact Advaxis?
Advaxis' mailing address is 305 COLLEGE ROAD EAST, PRINCETON NJ, 08540. The biotechnology company can be reached via phone at 609-452-9813 or via email at [email protected]
MarketBeat Community Rating for Advaxis (NASDAQ ADXS)
MarketBeat's community ratings are surveys of what our community members think about Advaxis and other stocks. Vote "Outperform" if you believe ADXS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADXS will underperform the S&P 500 over the long term. You may vote once every thirty days.
